CA2451932A1 - Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases - Google Patents
Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases Download PDFInfo
- Publication number
- CA2451932A1 CA2451932A1 CA002451932A CA2451932A CA2451932A1 CA 2451932 A1 CA2451932 A1 CA 2451932A1 CA 002451932 A CA002451932 A CA 002451932A CA 2451932 A CA2451932 A CA 2451932A CA 2451932 A1 CA2451932 A1 CA 2451932A1
- Authority
- CA
- Canada
- Prior art keywords
- ny1y2
- compound according
- alkyl
- effective amount
- ny3y4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention se rapporte à des composés représentés par la formule (I) ainsi qu'à des N-oxydes, des promédicaments, des bioisostères acides, des sels ou solvates pharmaceutiquement acceptables de ces composés, ou des N-oxydes, des promédicaments ou des bioisostères acides de ces sels ou solvates. L'invention se rapporte également à des compositions contenant ces composés ainsi qu'à des procédés de traitement consistant à administrer, à un patient justiciable d'un tel traitement, ces composés et compositions.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
GB0115393.1 | 2001-06-23 | ||
US30167801P | 2001-06-28 | 2001-06-28 | |
US60/301,678 | 2001-06-28 | ||
PCT/GB2002/002835 WO2003000695A1 (fr) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2451932A1 true CA2451932A1 (fr) | 2003-01-03 |
CA2451932C CA2451932C (fr) | 2009-12-29 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002451932A Expired - Fee Related CA2451932C (fr) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (fr) |
JP (1) | JP4344607B2 (fr) |
CN (1) | CN1294135C (fr) |
AU (1) | AU2002314325B8 (fr) |
BR (1) | BR0210652A (fr) |
CA (1) | CA2451932C (fr) |
CZ (1) | CZ20033443A3 (fr) |
EA (1) | EA007415B1 (fr) |
EC (1) | ECSP034922A (fr) |
EE (1) | EE05432B1 (fr) |
GB (1) | GB0115393D0 (fr) |
HU (1) | HUP0400300A3 (fr) |
ME (1) | MEP19308A (fr) |
NZ (1) | NZ529766A (fr) |
OA (1) | OA12632A (fr) |
PL (1) | PL374096A1 (fr) |
RS (1) | RS51698B (fr) |
SK (1) | SK15882003A3 (fr) |
TN (1) | TNSN03144A1 (fr) |
TR (1) | TR200302242T2 (fr) |
UA (1) | UA76760C2 (fr) |
WO (1) | WO2003000695A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
MXPA06005578A (es) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
JP2007512316A (ja) * | 2003-11-25 | 2007-05-17 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症の治療方法 |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
FR2876103B1 (fr) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
US7576053B2 (en) | 2005-06-13 | 2009-08-18 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
RS54181B9 (sr) | 2005-12-13 | 2020-01-31 | Incyte Holdings Corp | Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
MY154969A (en) | 2007-06-13 | 2015-08-28 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CA2711777A1 (fr) | 2008-01-11 | 2009-08-13 | Natco Pharma Limited | Nouveaux derives de pyrazolo [3, 4 -d] pyrimidine en tant qu'agents anticancereux |
CN102118968A (zh) | 2008-06-10 | 2011-07-06 | 雅培制药有限公司 | 新的三环化合物 |
MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
WO2011018894A1 (fr) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
KR20170118230A (ko) * | 2009-12-01 | 2017-10-24 | 애브비 인코포레이티드 | 신규한 트리사이클릭 화합물 |
KR102283091B1 (ko) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Jak抑制劑的局部製劑 |
CA2818545C (fr) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN102093364B (zh) | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2869954C (fr) | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Composes heterobicycliques substitues, compositions et applications medicales associees aux etats medicaux associes a la modulation de l'activite de la tyrosine kinase de bruton |
WO2013173720A1 (fr) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak |
KR101916443B1 (ko) | 2012-07-26 | 2018-11-08 | 글락소 그룹 리미티드 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
MX2015002887A (es) * | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
KR20210037012A (ko) | 2012-11-15 | 2021-04-05 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
NZ711976A (en) | 2013-03-06 | 2019-01-25 | Incyte Holdings Corp | Processes and intermediates for making a jak inhibitor |
US8969375B2 (en) | 2013-03-13 | 2015-03-03 | Abbvie, Inc. | CDK9 kinase inhibitors |
AU2014244183A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
US9073922B2 (en) | 2013-03-14 | 2015-07-07 | Abbvie, Inc. | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors |
EP2970299A1 (fr) * | 2013-03-14 | 2016-01-20 | Abbvie Inc. | Inhibiteurs de pyrrolopyrimidine cdk9 kinase |
EP2970264A1 (fr) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase |
SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
CN104804001B9 (zh) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
US20190046527A1 (en) | 2017-03-09 | 2019-02-14 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
WO2019113487A1 (fr) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs |
EP3746429B1 (fr) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) |
EA202092343A1 (ru) | 2018-03-30 | 2021-01-20 | Инсайт Корпорейшн | Лечение гнойного гидраденита с использованием ингибиторов jak |
AU2019353144B2 (en) | 2018-10-05 | 2023-11-16 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1441497A (en) * | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
JP2000505109A (ja) * | 1996-11-27 | 2000-04-25 | ファイザー・インク | 縮合二環式ピリミジン誘導体 |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
ID26698A (id) * | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
NZ510587A (en) * | 1998-09-18 | 2003-11-28 | Abbott Gmbh & Co | 4-aminopyrrolopyrimidines as kinase inhibitors |
PT1382339E (pt) * | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 EE EEP200400003A patent/EE05432B1/xx not_active IP Right Cessation
- 2002-06-21 CA CA002451932A patent/CA2451932C/fr not_active Expired - Fee Related
- 2002-06-21 EP EP02740895A patent/EP1404676A1/fr not_active Withdrawn
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/fr active Application Filing
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA200400073A1 (ru) | 2004-08-26 |
CA2451932C (fr) | 2009-12-29 |
AU2002314325B8 (en) | 2009-01-29 |
TR200302242T2 (tr) | 2004-12-21 |
WO2003000695A1 (fr) | 2003-01-03 |
EE05432B1 (et) | 2011-06-15 |
UA76760C2 (uk) | 2006-09-15 |
BR0210652A (pt) | 2004-08-10 |
OA12632A (en) | 2006-06-14 |
MEP19308A (en) | 2010-06-10 |
TNSN03144A1 (en) | 2005-12-23 |
WO2003000695A8 (fr) | 2004-03-11 |
EA007415B1 (ru) | 2006-10-27 |
AU2002314325B2 (en) | 2009-01-08 |
JP2005508300A (ja) | 2005-03-31 |
PL374096A1 (en) | 2005-09-19 |
ECSP034922A (es) | 2004-04-28 |
NZ529766A (en) | 2008-11-28 |
CN1518552A (zh) | 2004-08-04 |
RS51698B (en) | 2011-10-31 |
EP1404676A1 (fr) | 2004-04-07 |
CZ20033443A3 (en) | 2004-03-17 |
RS99203A (en) | 2006-12-15 |
JP4344607B2 (ja) | 2009-10-14 |
HUP0400300A2 (en) | 2007-08-28 |
HUP0400300A3 (en) | 2010-12-28 |
SK15882003A3 (sk) | 2004-07-07 |
GB0115393D0 (en) | 2001-08-15 |
EE200400003A (et) | 2004-02-16 |
CN1294135C (zh) | 2007-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2451932A1 (fr) | Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases | |
JP2023144075A (ja) | 癌治療用ptpn11(shp2)阻害剤としての6-(4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル)-3-(2,3-ジクロロフェニル)-2-メチルピリミジン-4(3h)-オン誘導体及び関連化合物 | |
JP4405602B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
CA2829117C (fr) | Nouveaux 6-arylaminopyridonecarboxamides comme inhibiteurs de mek | |
FI935379A0 (fi) | Katekoldietrar som fungerar som selektiva PDEIV-inhibitorer | |
JP2005508300A5 (fr) | ||
JP6380777B2 (ja) | PI3K、mTOR阻害薬としての縮合キノリン化合物 | |
RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
CA2565852C (fr) | Derives de phenol et de thiophenol 3- ou 4-monosubstitues utiles en tant que ligands h3 | |
CA2395593A1 (fr) | Azaindoles | |
WO2013072825A1 (fr) | Dérivés de phtalazinone en tant qu'inhibiteurs de mpges-1 | |
JP2012500831A (ja) | 新規なウレアおよびチオウレア誘導体 | |
RU2013148405A (ru) | Ингибиторы киназ | |
AU2010319398B2 (en) | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer | |
WO2018035346A1 (fr) | Composés inhibiteurs de kinase, compositions et méthodes de traitement du cancer | |
CA3203205A1 (fr) | Combinaisons pharmaceutiques d'inhibiteurs de sos1 pour le traitement et/ou la prevention du cancer | |
NZ515407A (en) | 4-Phenyl-pyrimidine derivatives | |
RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
ES2901452T3 (es) | Compuesto de pirimidina | |
WO2019028059A1 (fr) | Composés anticancéreux/anti-fibrose | |
JP2003519144A5 (fr) | ||
ES2777550T3 (es) | Profármaco de roflumilast | |
JP6870064B2 (ja) | ピリミジン化合物の医薬用途 | |
US11691973B2 (en) | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | |
JP2024047569A (ja) | Mek阻害剤としての3,4-ジヒドロ-2,7-ナフチリジン-1,6(2h,7h)-ジオン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130621 |